Journal
ATHEROSCLEROSIS
Volume 196, Issue 2, Pages 497-504Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2007.09.018
Keywords
ceramide; atherosclerosis; homocysteine; C-reactive protein; lipids
Funding
- NCCIH NIH HHS [R21 AT003094-01, R21 AT003094, AT003094] Funding Source: Medline
- NHLBI NIH HHS [R01 HL083471, R01 HL065916-02, HL076345, K08 HL076345, R01 HL083471-02, HL72716, K08 HL076345-02, HL65916, R01 HL065916, R01 HL072716-02, HL083471, R01 HL072716] Funding Source: Medline
- NIBIB NIH HHS [R01 EB002436, R01 EB002436-02, EB-002436] Funding Source: Medline
- NIDCR NIH HHS [R01 DE015543, R01 DE015543-02, DE15543] Funding Source: Medline
Ask authors/readers for more resources
Plasma sphingomyelin concentration is correlated with the development of atherosclerosis. It has been found to exist in significantly higher concentrations in aortic plaque. This appears to have clinical relevance as well as it has been shown to be an independent predictor of coronary artery disease. Ceramide, the backbone of sphingolipids, is the key component which affects atherosclerotic changes through its important second-messenger role. This paper sheds light on some of the current literature supporting the significance of ceramide with respect to its interactions with lipids, inflammatory cytokines, homocysteine and matrix metalloproteinases. Furthermore, the potential therapeutic implications of modulating ceramide concentrations are also discussed. (c) 2007 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available